Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$34.9 million.

  • Sangamo Therapeutics' Profit After Tax fell 42730.51% to -$34.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.9 million, marking a year-over-year increase of 1923.09%. This contributed to the annual value of -$97.9 million for FY2024, which is 6201.35% up from last year.
  • Sangamo Therapeutics' Profit After Tax amounted to -$34.9 million in Q3 2025, which was down 42730.51% from -$20.0 million recorded in Q2 2025.
  • Over the past 5 years, Sangamo Therapeutics' Profit After Tax peaked at $21.1 million during Q1 2023, and registered a low of -$114.5 million during Q2 2023.
  • Moreover, its 5-year median value for Profit After Tax was -$44.0 million (2022), whereas its average is -$42.7 million.
  • As far as peak fluctuations go, Sangamo Therapeutics' Profit After Tax plummeted by 297664.52% in 2021, and later skyrocketed by 14805.47% in 2023.
  • Over the past 5 years, Sangamo Therapeutics' Profit After Tax (Quarter) stood at -$37.5 million in 2021, then tumbled by 38.61% to -$52.0 million in 2022, then dropped by 16.01% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
  • Its last three reported values are -$34.9 million in Q3 2025, -$20.0 million for Q2 2025, and -$30.6 million during Q1 2025.